Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to September 2026.

37,204

Total recall recordsAll FDA and USDA recalls in Public Health Trace

9,841

Class I recallsReasonable probability of serious health consequences

24,366

Class II recallsTemporary or medically reversible health consequences

2,892

Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls

Most common hazardLack of Assurance of Sterility 2,073 recalls

Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sierra-nevada-cheese-company-recalls-graziers-raw-milk-cheese-because-possible-health-riskPublished September 28, 2026

Most affected stateHawaii 200 recalls mention this state

State: AS ×
Clear all

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters

Timeline Classification Table

Metric

Time range

Group by

View

Recalls announced by month (Year to date)

Download CSV

Source: FDA and USDA public dataLast updated October 1, 2026 ET

Summary (Year to date)

1,714 recalls have been announced year to date.
Sep 2026 was 3% higher than the previous complete period (Aug 2026: 182).
The highest complete period was Jun 2026 (297).
Oct 2026 is incomplete and not included in the figures above.

Complete data
Incomplete

Recalls by class

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

Download CSV

Recalls by class
Class	Recalls
Class II	24,366
Class I	9,841
Class III	2,892
Not Yet Classified	2

FDA Recall Terminated Historical recordClass III

Amoxicillin for Oral Suspension, USP 400mg/5mL, NDC 0093-4161-78 (75ml) and 0093-4161-73 (100mL)

by Teva Pharmaceuticals USA, Inc.

Reason: Discoloration: This recall is being carried out due to a yellow to brown discolored Amoxicillin powder on the inner foil seal of the bottles.
Published: June 19, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Cefazolin, injection, 1 gram per vial, 25 vials per box, sterile, Rx only, single-use vial, Manufactured in Austria by Sandoz GmbH for Sandoz, Inc. Princeton, NJ 08540, NDC 00781-3451-70 (vial), NDC 00781-3451-96 (box)

by Sandoz Incorporated

Reason: Lack of Assurance of Sterility: Sandoz Inc is recalling Cefazolin for Injection, USP 1 gm vials, lot DB2208, due to a customer complaint for broken/cracked vials which was confirmed through review of retained samples.
Published: June 19, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Voltaren 1% Gel, 100 gm tube, Rx only, Dist By: Physicians Total Care, Tulsa OK 74146, Mfg By: Novartis Consumer Health, Parsippany, NJ 07054, NDC 54868-5965-00

by Physicians Total Care, Inc.

Reason: Labeling: Incorrect or Missing Lot and/or Expiration Date; This recall is being initiated because the lot number and expiration date on the tube may not be legible.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Disulfiram Tablets USP 250 mg, 100 tablet bottle, Rx only, Manufactured for TEVA Pharmaceuticals, USA, Sellersville, PA --- NDC 0093-5035-01

by Teva Pharmaceuticals USA, Inc.

Reason: CGMP Deviation; cotton coil is missing in some packaged bottles
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Voltaren Gel (diclofenac sodium topical gel) 1%, for topical use only, RX only, a) Packaged in 20 gm tubes, NDC 63481-684-83 (physician sample product) and b) 100 gm tubes, NDC 63481-684-47 (the 100 g tubes are also packaged 3/100-g tubes/packs (UPC code: 363481684030 NDC code: 6348168403) and 5/100-g tubes/packs (UPC code: 363481684054 NDC code: 6348168405), Marketed by Endo Pharmaceuticals Inc., Chadds Ford, PA and Manufactured by Novartis Consumer Health, Inc, Parsippany, NJ.

by Novartis Consumer Health

Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Lamisil AT Cream (terbinafine hydrochloride 1% antifungal), 12 gm ( .42 oz) Tubes and 30 gm (1 oz) Tubes packaged in one box, Novartis Consumer Health, Inc., Parsitan, NJ. UPC code: 300676249438. (Club Pack), NDC 0067-6295-43

by Novartis Consumer Health

Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Novartis Lamisil AT Cream for Jock Itch (terbinafine hydrochloride 1% antifungal), a) 12 g (.42 oz) Tube, NDC 0067-3999-12, Novartis Consumer Health, Inc., Parsitan, NJ. UPC code: 300673999121, (Vertical Pack) and b) packaged in a horizontal package12 gm (.42 oz) Tube, NDC 0067-3999-42, Novartis Consumer Health, Inc., Parsippany, NJ. UPC code: 300673999428.

by Novartis Consumer Health

Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Target Up & Up, athlete's foot cream, full prescription strength, terbinafine hydrochloride 1% antifungal, 30 g (1 oz), compare to active ingredient in Lamisil, NDC 0067-6382-30 & UPC code: 300676382302 (Novartis) Target NDC 1167-3401-04, Distributed by Target Corp., Minneapolis, MN.

by Novartis Consumer Health

Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot..
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Novartis Lamisil AT Cream, Terbinafine Hydrochloride Cream 1% Antifungal, Novartis Consumer Health, Inc., Parsippany, NJ. (a)12 gm (.42 oz), packaged with UPC code 300673998421 and NDC code: 0067-3998-42; (b) 12 gm (.42 oz), packaged with UPC code: 300673998124 and NDC code: 0067-3998-12; (c) 30 gm (1 oz), packaged with UPC code: 300673998308 and NDC code: 0067-3998-30; (d) 30 gm (1 oz), packaged with UPC code: 300673998339 and NDC code: 0067-3998-33.

by Novartis Consumer Health

Reason: Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Metronidazole Tablets, USP, 500 mg, packaged in a) 10-count tablets per bottle (NDC 54868-0158-3); b) 14-count tablets per bottle (NDC 54868-0158-1); c) 20-count tablets per bottle (NDC 54868-0158-5); d) 21-count tablets per bottle (NDC 54868-0158-0); e) 30-count tablets per bottle (NDC 54868-0158-8), Rx only, Mfg. By: Pliva Krakow Pharma. Comp., Krakow, Poland; Repacked & distributed by: Physicians Total Care, Inc., Tulsa, OK 74146.

by Physicians Total Care, Inc.

Reason: Failed Tablet/Capsule Specifications: Some tablets had the potential to not conform to weight specifications.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

DOBUTamine in 5% Dextrose Injection, USP, 250 mg Total, 1000 mcg/mL 250 mL bag, Rx only, HOPIRA, INC., LAKE FOREST, IL 60045 NDC 0409-2346-32

by Hospira Inc.

Reason: Lack of Assurance of Sterility: Confirmed report of leaking in the primary container.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Diazepam Injection, USP 5 mg/mL, 10 mL, Multiple-dose fliptop vial, RX only, HOSPIRA, INC. LAKE FOREST, IL 60045 USA, NDC 0409-3213-12

by Hospira Inc.

Reason: Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial.
Published: June 12, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01), Rx only, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. Made in India

by Mylan Pharmaceuticals Inc.

Reason: Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets..
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Lisinopril Tablets, USP, 30 mg, Rx only, 100 tablets, NDC 65862-041-01 Manufactured for: Aurobindo Pharma USA Inc. 2400 Route 130 North, Dayton, NJ 08810 Manufactured by: Aurobindo Pharma Limited Hyderabad- 500 072 India

by Aurobindo Pharma USA Inc

Reason: Labeling: Label Error on Declared Strength: Incorrect strength on side display panel of label
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Camrese(TM) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg and Ethinyl Estradiol 0.01 Tablets, 2 Extended-Cycle Tablet Dispensers (NDC 0093-3134-82) and 1 Extended-Cycle Tablet Dispenser NDC 0093-3134-91), 91 Tablets Each, Rx only, TEVA Womens Health Inc., Subsidiary of TEVA Pharmaceuticals, Inc., Sellersville, PA

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass III

Seasonale(R) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg, 3 extended-cycle tablet dispensers, 91 tablets each, Rx only, TEVA Women Health, Inc., Subsidiary of TEVA Pharmaceuticals USA, Inc., Sellersville, PA NDC 51285-058-66

by Teva Pharmaceuticals USA, Inc.

Reason: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Pyridoxine 100mg/ml Inj MDV, 1X30 ml 30 day expiration,

by Nora Apothecary and Alternative Therapies, Inc.

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Meperidine 100mg/ml MDV, 5ml 90 day expiration,

by Nora Apothecary and Alternative Therapies, Inc.

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

Lidocaine 2% Inj MDV, 20 ml 30 day expiration,

by Nora Apothecary and Alternative Therapies, Inc.

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Published: June 5, 2013
Distribution: Nationwide

View recall →

FDA Recall Terminated Historical recordClass II

M.I.C.+B12 Inj MDV: 3x50ml, 4x50 ml 90 day expiration,

by Nora Apothecary and Alternative Therapies, Inc.

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Published: June 5, 2013
Distribution: Nationwide

View recall →

Data last updated: October 1, 2026 ET

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.